Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Kalinski, Pawel, MD, PhD
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07634094CT.gov Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
NCT07410676CT.gov EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07261683CT.gov Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer | — | Recruiting | — | — | — |
NCT06843447CT.gov A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) | — | Recruiting | — | — | — |
NCT05952453CT.gov Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro | — | Recruiting | — | — | — |
NCT06513624CT.gov ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers | — | Recruiting | — | — | — |
NCT06083844CT.gov Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy | — | Recruiting | — | — | — |
NCT05985655CT.gov Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05797168CT.gov Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors | — | Recruiting | — | — | — |
NCT05824975CT.gov A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | — | Recruiting | — | — | — |
Show 69 more trialsShow fewer
NCT05787587CT.gov A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05746897CT.gov A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05467670CT.gov Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT05708950CT.gov A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | — | Completed | — | — | — |
NCT05446298CT.gov ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT05431582CT.gov Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | — | Withdrawn | — | — | — |
NCT05579366CT.gov Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | — | Recruiting | — | — | — |
NCT05572684CT.gov A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05256381CT.gov A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05395052CT.gov FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05271318CT.gov Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. | — | Active Not Recruiting | — | — | — |
NCT05311618CT.gov Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | — | Unknown | — | — | — |
NCT05215574CT.gov Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04575961CT.gov Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT05081609CT.gov A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | — | Active Not Recruiting | — | — | — |
NCT05092360CT.gov Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) | — | Terminated | — | — | — |
NCT05116189CT.gov Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). | — | Active Not Recruiting | — | — | — |
NCT05368207CT.gov Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient | — | Unknown | — | — | — |
NCT05187338CT.gov Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05086692CT.gov A Beta-only IL-2 ImmunoTherapY Study | — | Recruiting | — | — | — |
NCT04713514CT.gov OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC | — | Active Not Recruiting | — | — | — |
NCT04913337CT.gov Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | — | Active Not Recruiting | — | — | — |
NCT04375956CT.gov Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients | — | Unknown | — | — | — |
NCT04752826CT.gov BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) | — | Recruiting | — | — | — |
NCT04417192CT.gov Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer | — | Completed | — | — | — |
NCT04691375CT.gov A Study of PY314 in Subjects With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04585750CT.gov The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | — | Recruiting | — | — | — |
NCT04361370CT.gov Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer | — | Enrolling By Invitation | — | — | — |
NCT04140526CT.gov Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | — | Active Not Recruiting | — | — | — |
NCT04332653CT.gov NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04354246CT.gov COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies | — | Completed | — | — | — |
NCT04205227CT.gov ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04244552CT.gov A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | — | Terminated | — | — | — |
NCT03761914CT.gov Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | — | Completed | — | — | — |
NCT04044859CT.gov ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | — | Active Not Recruiting | — | — | — |
NCT04234113CT.gov Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT03430700CT.gov Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer | — | Completed | — | — | — |
NCT03872947CT.gov A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03797326CT.gov Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | — | Completed | — | — | — |
NCT03734692CT.gov Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT03836352CT.gov Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03740165CT.gov Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | — | Completed | — | — | — |
NCT03596281CT.gov Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer | — | Completed | — | — | — |
NCT03621982CT.gov Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03755739CT.gov Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT03412877CT.gov Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer | — | Recruiting | — | — | — |
NCT03539328CT.gov Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer | — | Unknown | — | — | — |
NCT03454451CT.gov CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | — | Completed | — | — | — |
NCT03410784CT.gov Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer | — | Unknown | — | — | — |
NCT03514121CT.gov FPA150 in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03428802CT.gov Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | — | Active Not Recruiting | — | — | — |
NCT03275506CT.gov PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer . | — | Completed | — | — | — |
NCT03029403CT.gov Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer | — | Active Not Recruiting | — | — | — |
NCT03311334CT.gov A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03329950CT.gov A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | — | Completed | — | — | — |
NCT03126812CT.gov Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer | — | Completed | — | — | — |
NCT02766582CT.gov Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer | — | Completed | — | — | — |
NCT02865811CT.gov Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer | — | Completed | — | — | — |
NCT02520154CT.gov Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | — | Completed | — | — | — |
NCT02657889CT.gov Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | — | Completed | — | — | — |
NCT02575807CT.gov Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer | — | Terminated | — | — | — |
NCT02608684CT.gov A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer | — | Completed | — | — | — |
NCT02537444CT.gov Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191) | — | Completed | — | — | — |
NCT02440425CT.gov Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | — | Completed | — | — | — |
NCT02452424CT.gov A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | — | Terminated | — | — | — |
NCT02298959CT.gov Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | — | Active Not Recruiting | — | — | — |
NCT02346955CT.gov Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | — | Terminated | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01174121CT.gov Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Kalinski, Pawel, MD, PhD | P3 | B · 60 |
| Tisotumab Vedotin | Seagen Inc. | P2 | BB |
| TIL | Inge Marie Svane | P2 | BB |
| Olaparib | Shandong University | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Kalinski, Pawel, MD, PhD | P3 | BB |
| Adriamycin | Genmab | P3 | BB |
| Carboplatin | Fudan University | P4 | BB |
| OTL-38 | On Target Laboratories, LLC | P4 | BB |
| Irinotecan | ARCAGY/ GINECO GROUP | P4 | BB |
+42 more in the Ovarian Cancer cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Ovarian Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-ovarian-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →